Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl M Gay

Showing results (1-10 of 80) with videos related to

Pageof 8
Sort By:
Translational Lung Cancer Research|October 24, 2025
Sacituzumab govitecan: another emerging treatment option for patients with relapsed small cell lung cancerBingnan Zhang, Carl M Gay
Translational Lung Cancer Research|November 19, 2020
Narrative review of the emerging role of molecular biomarkers in guiding the definitive management of unresectable non-small cell lung cancerEric K Singhi, Carl M Gay
The Journal of Thoracic and Cardiovascular Surgery|April 5, 2025
Timing of local consolidative pulmonary resection for oncogene-driven stage IV lung cancerMara B Antonoff, Carl M Gay
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2019
PARP Inhibition Combined with Immune Checkpoint Blockade in SCLC: Oasis in an Immune Desert or Mirage?Carl M Gay, Lauren A Byers
British Journal of Cancer|January 11, 2017
Giving AXL the axe: targeting AXL in human malignancyCarl M Gay, Kavitha Balaji, Lauren Averett Byers
Translational Lung Cancer Research|March 15, 2018
Targeting DNA damage repair in small cell lung cancer and the biomarker landscapeTriparna Sen, Carl M Gay, Lauren Averett Byers
Developmental Biology|October 1, 2010
Diverse functions for the semaphorin receptor PlexinD1 in development and diseaseCarl M Gay, Tomasz Zygmunt, Jesús Torres-Vázquez
Cancer Cell|January 18, 2020
This Is Our Cells Under Pressure: Decreased DNA Damage Repair in Response to Targeted Therapies Facilitates the Emergence of Drug-Resistant ClonesCarl M Gay, Christine M Parseghian, Lauren Averett Byers
Nature Cancer|June 5, 2025
The current and emerging immunotherapy paradigm in small-cell lung cancerKang Qin, Carl M Gay, Lauren A Byers, et al.
Cancer|January 9, 2019
Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint eraCarminia M Della Corte, Carl M Gay, Lauren A Byers
Pageof 8

Showing results (1-10 of 80) with videos related to

Sort By:
Pageof 8
Translational Lung Cancer Research|October 24, 2025
Sacituzumab govitecan: another emerging treatment option for patients with relapsed small cell lung cancerBingnan Zhang, Carl M Gay
Translational Lung Cancer Research|November 19, 2020
Narrative review of the emerging role of molecular biomarkers in guiding the definitive management of unresectable non-small cell lung cancerEric K Singhi, Carl M Gay
The Journal of Thoracic and Cardiovascular Surgery|April 5, 2025
Timing of local consolidative pulmonary resection for oncogene-driven stage IV lung cancerMara B Antonoff, Carl M Gay
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2019
PARP Inhibition Combined with Immune Checkpoint Blockade in SCLC: Oasis in an Immune Desert or Mirage?Carl M Gay, Lauren A Byers
British Journal of Cancer|January 11, 2017
Giving AXL the axe: targeting AXL in human malignancyCarl M Gay, Kavitha Balaji, Lauren Averett Byers
Translational Lung Cancer Research|March 15, 2018
Targeting DNA damage repair in small cell lung cancer and the biomarker landscapeTriparna Sen, Carl M Gay, Lauren Averett Byers
Developmental Biology|October 1, 2010
Diverse functions for the semaphorin receptor PlexinD1 in development and diseaseCarl M Gay, Tomasz Zygmunt, Jesús Torres-Vázquez
Cancer Cell|January 18, 2020
This Is Our Cells Under Pressure: Decreased DNA Damage Repair in Response to Targeted Therapies Facilitates the Emergence of Drug-Resistant ClonesCarl M Gay, Christine M Parseghian, Lauren Averett Byers
Nature Cancer|June 5, 2025
The current and emerging immunotherapy paradigm in small-cell lung cancerKang Qin, Carl M Gay, Lauren A Byers, et al.
Cancer|January 9, 2019
Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint eraCarminia M Della Corte, Carl M Gay, Lauren A Byers
Pageof 8